Document is current
Any future updates will be listed below
-
Authors
Lai, Anne Y
Sorrentino, Jessica A
Dragnev, Konstantin H
Weiss, Jared M
Owonikoko, Taofeek K https://orcid.org/0000-0002-7724-7728
Rytlewski, Julie A
Hood, Jill
Yang, Zhao
Malik, Rajesh K
Strum, Jay C
Roberts, Patrick J
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02499770 at ClinicalTrials.govnct02499770 at ClinicalTrials.govDocuments that mention this clinical trial
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
https://doi.org/10.1136/jitc-2020-000847
nct02499770 at ClinicalTrials.govDocuments that mention this clinical trial
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
https://doi.org/10.1136/jitc-2020-000847
Documents that mention this clinical trial
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
https://doi.org/10.1136/jitc-2020-000847
-
Funding
Funding for this research was provided by:
G1 Therapeutics, Inc.
- License Information
